Lannett Co (Lannett Co) Change In Working Capital : $-8.1 Mil (TTM As of Mar. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Lannett Co Change In Working Capital?

Lannett Co's change in working capital for the quarter that ended in Mar. 2023 was $7.1 Mil.

Lannett Co's change in working capital for the fiscal year that ended in Jun. 2022 was $29.1 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Lannett Co Change In Working Capital Historical Data

The historical data trend for Lannett Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lannett Co Change In Working Capital Chart

Lannett Co Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Change In Working Capital

Get a 7-Day Free Trial

-65.75

51.67

28.36

-16.62

29.05

Lannett Co Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Change In Working Capital	Get a 7-Day Free Trial															9.49	-6.67	-0.08	-8.43	7.08

Lannett Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.1 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Lannett Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Lannett Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Lannett Co (Lannett Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lannett Co Inc (OTCPK:LCINQ) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1150 Northbrook Drive, Suite 155, Trevose, PA, USA, 19053

Website

https://www.lannett.com

Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory, and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.

Executives

John C Chapman	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Timothy C Crew	officer: Chief Executive Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
Patrick G Lepore	director	17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Melissa Rewolinski	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Jeffrey Farber	officer: Secretary
Samuel H Israel	officer: Chief Legal Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
John Abt	officer: Vice President of Quality	9000 STATE ROAD, PHILADELPHIA PA 19136
John Kozlowski	officer: Chief Operating Officer	9000 STATE ROAD, PHILADELPHIA PA 19136
David A Drabik	director	9000 STATE RD, PHILADELPHIA PA 19136
Paul Taveira	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Albert Iii Paonessa	director	9852 NW 2ND COURT, PLANTATION FL 33324
Kevin Smith	other: Vice President
Maureen Cavanaugh	officer: Senior Vice President and CCOO	9000 STATE ROAD, PHILADELPHIA PA 19136
David Farber	officer: Treasurer
Arthur P Bedrosian	officer: President	P O BOX D 1400, POMONA NY 10970